Uni-Bio Science Group Announces 2026 Interim Results
- Written by: Viw Magazine
Revenue Reached HK$ 273.8M, Driven by Solid Growth from Bogutai®
Innovation-Driven Transformation Progresses with Portfolio Optimization and Broader Market Access
Innovation-Driven Transformation Progresses with Portfolio Optimization and Broader Market Access
HONG KONG SAR – EQS Newswire – 26 August 2026 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its interim results for the six months ended 30 June 2026 (the "Period").
